메뉴 건너뛰기
Multiple Sclerosis Journal
Volumn 18, Issue 11, 2012, Pages 1661-1662
Response to GS gronseth and e ashman
Author keywords

[No Author keywords available]
Indexed keywords

EVIDENCE BASED MEDICINE; HUMAN; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;
EID: 84868034042     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512463484     Document Type: Letter
Times cited : (2)
References (10)
  • 1
    • 84863191947 scopus 로고    scopus 로고
    • The AAN response to evidence-based medicine: Promise and pitfalls
    • Gronseth GS, Ashman E. The AAN response to evidence-based medicine: Promise and pitfalls. Mult Scler. 2102 ; 18: 947-948
    • Mult Scler , vol.18 , pp. 947-948
    • Gronseth, G.S.1    Ashman, E.2
  • 2
    • 84863188715 scopus 로고    scopus 로고
    • Evidence-based medicine: Promise and pitfalls
    • Goodin DS, Reder AT. Evidence-based medicine: Promise and pitfalls. Mult Scler. 2102 ; 18: 949-950
    • Mult Scler , vol.18 , pp. 949-950
    • Goodin, D.S.1    Reder, A.T.2
  • 3
    • 84860770990 scopus 로고    scopus 로고
    • Survival in MS: A randomized cohort-study 21 years after the start of the pivotal IFNβ-1b trial
    • Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: A randomized cohort-study 21 years after the start of the pivotal IFNβ-1b trial. Neurology. 2012 ; 78: 1315-1322
    • (2012) Neurology , vol.78 , pp. 1315-1322
    • Goodin, D.S.1    Reder, A.T.2    Ebers, G.C.3
  • 4
    • 84863895902 scopus 로고    scopus 로고
    • Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis
    • Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012 ; 308: 247-256
    • (2012) JAMA , vol.308 , pp. 247-256
    • Shirani, A.1    Zhao, Y.2    Karim, M.E.3
  • 6
    • 84949752364 scopus 로고    scopus 로고
    • 2nd ed.Hoboken, NJ: John Wiley & Sons Inc., 2005. Hoboken, NJ: John Wiley & Sons Inc.;
    • Piantadosi S Clinical trials: A methodologic perspective. 2 nd ed.Hoboken, NJ: John Wiley & Sons Inc., 2005. Hoboken, NJ: John Wiley & Sons Inc. ; 2005 :
    • (2005) Clinical Trials: A Methodologic Perspective
    • Piantadosi, S.1
  • 7
    • 0037108235 scopus 로고    scopus 로고
    • Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems
    • Pocock SJ, Assmann SE, Enos LE, et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems. Stat Med. 2002 ; 21: 2917-2930
    • (2002) Stat Med , vol.21 , pp. 2917-2930
    • Pocock, S.J.1    Assmann, S.E.2    Enos, L.E.3
  • 9
    • 82955236170 scopus 로고    scopus 로고
    • A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis
    • Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology. 2011 ; 77: 1611-1618
    • (2011) Neurology , vol.77 , pp. 1611-1618
    • Stein, M.S.1    Liu, Y.2    Gray, O.M.3
  • 10
    • 84862776780 scopus 로고    scopus 로고
    • Relationship between early clinical characteristics and long-term disability outcomes: 16-year follow-up of the pivotal IFNB-1b study in MS
    • Goodin DS, Traboulsee A, Knappertz V, et al. Relationship between early clinical characteristics and long-term disability outcomes: 16-year follow-up of the pivotal IFNB-1b study in MS. J Neurol Neurosurg Psychiatry. 2012 ; 83: 282-287
    • (2012) J Neurol Neurosurg Psychiatry , vol.83 , pp. 282-287
    • Goodin, D.S.1    Traboulsee, A.2    Knappertz, V.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.